Steel Grove Capital Advisors LLC Acquires Shares of 2,435 Edwards Lifesciences Co. (NYSE:EW)

Steel Grove Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,435 shares of the medical research company’s stock, valued at approximately $225,000.

Other large investors have also modified their holdings of the company. Altshuler Shaham Ltd boosted its stake in shares of Edwards Lifesciences by 100.4% during the second quarter. Altshuler Shaham Ltd now owns 16,541 shares of the medical research company’s stock valued at $1,528,000 after acquiring an additional 8,286 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Edwards Lifesciences by 42.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 932 shares of the medical research company’s stock worth $86,000 after purchasing an additional 280 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $1,920,000. Fidelis Capital Partners LLC grew its stake in Edwards Lifesciences by 10.0% during the 2nd quarter. Fidelis Capital Partners LLC now owns 5,571 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 507 shares in the last quarter. Finally, Frank Rimerman Advisors LLC grew its stake in Edwards Lifesciences by 32,257.1% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 6,795 shares of the medical research company’s stock valued at $628,000 after purchasing an additional 6,774 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several research reports. Daiwa America upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. Piper Sandler cut their target price on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a research note on Thursday, July 25th. Citigroup boosted their price objective on Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. JPMorgan Chase & Co. cut Edwards Lifesciences from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $105.00 to $72.00 in a report on Thursday, July 25th. Finally, Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Sixteen research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.82.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $4,378,659.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock worth $1,218,138 in the last quarter. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Up 0.7 %

Shares of NYSE:EW opened at $67.33 on Tuesday. The company has a market capitalization of $40.57 billion, a PE ratio of 29.02, a price-to-earnings-growth ratio of 2.85 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The business has a fifty day moving average price of $69.45 and a two-hundred day moving average price of $82.61. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the prior year, the firm posted $0.66 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. Analysts forecast that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.